ShareValue scores for MANGALAM.NSE: Valuation 69, Quality 26, Growth 22, Health 47.

MANGALAM.NSE
NSE

Mangalam Drugs And Organics Limited

₹27.01(-0.18%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

5% to 17%
Valuation
69
Fair Value
Price vs Value
Quality
26
Weak
Business Strength
Growth
22
Weak
Revenue & Earnings
Health
47
Moderate
Financial Stability
Momentum
53
Neutral
Price Trend

Company Details

About

Mangalam Drugs & Organics Limited, together with its subsidiary, manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers active pharmaceutical ingredients (API) products, including acyclovir, amodiaquine, artemether, artesunate, bisoprolol fumarate, chloroquine phosphate, dihydroartemisinin, dolutegravir sodium, efavirenz, emtricitabine, etodolac, furosemide, hydroxychloroquine sulphate, lumefantrine, nimesulide, nitrofurantoin anhydrous and monohydrate, olanzapine, primaquine and piperaquine phosphate, pyrimethamine, pyronaridine tetraphosphate, sulfadoxine, tenofovir alafenamide hemifumarate, and tenofovir disoproxil fumarate. It also provides intermediates, such as 2-dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-dichloro-5-methoxy pyrimidine; 4,7 dichloroquinoline; ortho phenoxy methane sulfonanilide; tenofovir alafenamide base; and tenofovir disoproxil base. In addition, the company offers specialty chemicals comprising l(+)menthol; 2,3-dihydrophthalazine-1, 4-dione or phthalazine-1,4-dione; and 4-cynoethyl-2-methy phenol. Further, it manufactures organic and inorganic chemicals, and heavy chemicals. Additionally, it offers active pharmaceutical ingredients; and products covering various therapeutic areas comprising anti-malaria, anti-retroviral, anti-hypertensive, anti-inflammatory, anti-convulsant, anti-viral, anti-rheumatic arthritis agents, and anti-bacterial, as well as develops product for anti-hypertensive indications. Mangalam Drugs & Organics Limited was incorporated in 1972 and is based in Mumbai, India.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026